First of all, Dr. Iinuma is to be congratulated for studying this population of patients. Patients with mental disabilities represent one of the largest populations in pediatric epilepsy. However, researchers generally tend to either not address this population as a special group, or to avoid such studies because of the behavior difficulties and other challenges.
The differences in the frequency of monotherapy in this study illustrate the difficulty in treating these patients. While monotherapy was used in 60% of the normally intelligent patients in this study, only 12% of those with intellectual disabilities were treated with single agents. The mean number of antiepileptic drugs (AEDs) was 1.6 for the first group versus 2.94 for the disabled group. Regardless of the seizure type, better overall control was attainable in the normally intelligent versus the intellectually disabled persons.
The incidence of adverse events was interesting, with 21% of the normal group experiencing side effects, 28% of the disabled, and 24% overall. Usually, adverse events are reported in the mentally disabled population at about 20-40%. This is due to the excess of behavioral abnormalities seen with so many of our current drugs.
Zonisamide appears to be an effective AED in both normal and intellectually deficient children. No special adverse effects were worsened in the intellectually challenged group. Overall, we need more double-blind, placebo-controlled, or comparative studies to determine which patients will respond most favorably to treatment. This study examined the responses of normal versus intellectually disabled children. We also need to better define the adverse effects profile of infants versus older children. For example, will a 5-year-old or 3-year-old mentally disabled child respond the same way as a 20-year-old mentally disabled individual? We currently do not know the answer.
For these special population groups, we also need to better define very specific abnormalities, such as behavior abnormalities, anorexia, weight loss, and hypohidrosis in particular. We need a strategy to handle these adverse effects. Will we reduce the drug? Discontinue the drug? There must be an available answer when the drug is being used in children.
US development must progress quickly to make zonisamide available to children, the mentally retarded population, and those with myoclonic syndromes of various types including progressive myoclonic epilepsy. However, we must be syndrome-specific in our recommendations. While the experience may be very good in a particular type of myoclonic syndrome, it may not be as beneficial in some of the other syndromes.
The once-or twice-a-day dosing is also an advantage. The 25 mg preparation is acceptable and would be welcomed, especially if it were available as a divisible or chewable tablet.
In conclusion, despite the introduction in the US of felbamate, lamotrigine, topiramate, gabapentin, levetiracetam and oxcarbazepine patients with progressive encephalopathic epilepsy still require additional agents. The data presented in this paper and others, certainly suggest that zonisamide may play an active role in meeting that need.
